Evidence map›Paper›PMID 40388656›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2025

Affinity-Based Protein Profiling Reveals IDH2 as a Mitochondrial Target of Cannabinol in Receptor-Independent Neuroprotection.

Eva Schaller, Stephanie Lamer, Andreas Schlosser, Christian Stigloher, Pamela Maher, Michael Decker

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Eva SchallerJulius-Maximilians-Universität Würzburg (JMU), Institute for Pharmacy and Food Chemistry, Pharmaceutical and Medicinal Chemistry, Am Hubland, 97074, Würzburg, Germany.
Stephanie LamerJulius-Maximilians-Universität Würzburg (JMU), Rudolf-Virchow-Zentrum - Center for Integrative and Translational Bioimaging, 97080, Würzburg, Germany.
Andreas SchlosserJulius-Maximilians-Universität Würzburg (JMU), Rudolf-Virchow-Zentrum - Center for Integrative and Translational Bioimaging, 97080, Würzburg, Germany.
Christian StigloherJulius-Maximilians-Universität Würzburg (JMU), Biocenter/Theodor-Boveri-Institute, Imaging Core Facility, Am Hubland, 97074, Würzburg, Germany.
Pamela MaherCellular Neurobiology Laboratory, The Salk Institute for Biological Studies, 10010 N Torrey Pines Road, La Jolla, California, 92037, USA.
Michael DeckerJulius-Maximilians-Universität Würzburg (JMU), Institute for Pharmacy and Food Chemistry, Pharmaceutical and Medicinal Chemistry, Am Hubland, 97074, Würzburg, Germany.ORCID https://orcid.org/0000-0002-6773-6245

Funding

Using geroscience to understand and treat Alzheimer's diseaseR01AG069206 · NIA · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI MAHER, PAMELA ANNE · 2020 to 2024
$4.0M
Bayerisch-Kalifornischen Hochschulzentrum (Bavarian Californian Technology Center) A1 [2022-1]Elitenetzwerk Bayern Marianne-Plehn-ProgrammNIA NIH HHS R01 AG069206Studienstiftung des Deutschen Volkes
6 · The paper itself

Abstract

Phytocannabinoids are attracting growing attention because of their potential for treatment of neurodegenerative diseases. Among them, the "minor" cannabinoid, cannabinol (CBN), has emerged as a promising neuroprotective agent, acting independently of classical cannabinoid receptors through as-yet unidentified mitochondrial targets. To uncover the molecular basis of its neuroprotective effects, we designed and synthesized a chemical probe based on CBN, incorporating a minimalist diazirine linker. Functional assays confirmed that the probe retains CBN's mitochondrial activity and exhibits strong mitochondrial enrichment, as demonstrated by fluorescence microscopy and click-correlative light and electron microscopy (click-CLEM). By affinity-based protein profiling (AfBPP), we identified isocitrate dehydrogenase 2 (IDH2) as a key mitochondrial target of CBN. This finding was further substantiated by siRNA knockdown studies, which revealed that the absence of IDH2 partially phenocopies CBN's effects, validating its role as a critical mediator of CBN's neuroprotective activity.

Indexed as

CannabinoidsIsocitrate DehydrogenaseMitochondriaNeuroprotective AgentsAnimalsHumansReceptors, CannabinoidRNA, Small InterferingCannabinoidsIDH2 protein, humanIsocitrate DehydrogenaseNeuroprotective AgentsReceptors, CannabinoidRNA, Small Interferingalzheimer's diseasemitochondrianatural productsneuroprotectionproteomics

Identifiers

PMID40388656
PMCPMC12160979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.